GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: CGT-8012 | CGT8012 | compound 8 [CN101899047A]
cetagliptin is an approved drug
Compound class:
Synthetic organic
Comment: Cetagliptin (CGT-8012) is an orally bioavailable, dipeptidyl peptidase 4 enzyme (DPP-4) inhibitor ('gliptin') class drug. It was designed as an antihyperglycemic agent to treat type 2 diabetes mellitus (T2DM) via inhibition of DPP-4-mediated catbolism of incretin hormones including glucagon-like peptide-1 (GLP-1) [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Ji L, Lu J, Gao L, Ying C, Sun J, Han J, Zhao W, Gao Y, Wang K, Zheng X et al.. (2023)
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial. Diabetes Obes Metab, 25 (12): 3671-3681. [PMID:37661308] |
2. Yu Q, Wei F. (2010)
Beta-amino tetrahydropyrazine, tetrahydropyrimidine and tetrahydropyridine used as dipeptidy peptidase inhibitors for curing or preventing diabetes. Patent number: CN101899047A. Assignee: Shengshi Taike Biopharmaceutical Technology Suzhou Co ltd. Priority date: 26/05/2009. Publication date: 01/12/2010. |